Gilead Sciences, headquartered in Foster City, California, announced layoffs affecting 108 workers at its Redwood City offices shortly after completing the acquisition of Arcellx Inc. for approximately $7.8 billion in early April 2020. The positions impacted include roles in manufacturing, quality assurance, marketing, sales, and clinical development, specifically noting that twelve senior directors and eleven vice presidents are among those losing their jobs. These employees will lose their jobs between June 30, 2021, and April 30, 2027, following the filing of a Worker Adjustment and Retraining Notification (WARN) with the California Employment Development Department. In addition to the Redwood City reductions, Gilead let go of 84 employees in Rockville, Maryland, as reported by the state's Department of Labor, and terminated another 34 positions at its Oceanside campus on March 27. A company spokesperson attributed these actions to integration following the Arcellx transaction, emphasizing that while such decisions are taken with difficulty, the focus remains on supporting employees during the transition. The executive vice president of Kite Pharma noted that the company's focus has shifted toward executing the acquisition and preparing to bring anito-cel patients into treatment. This round of layoffs occurs within a broader trend of consolidation and job cuts in the Bay Area biotech sector, particularly following an influx of investment during the pandemic which recently gave way to mass layoffs, slashed drug pipelines, and bankruptcies among industry peers like Pfizer, which abandoned its South San Francisco office.